Last updated: February 22, 2026
What is NDC 00555-0483?
NDC 00555-0483 corresponds to Benznidazole, an anti-parasitic drug primarily used for treating Chagas disease. It is approved in the United States under an FDA accelerated approval pathway, with broader use in countries with high Chagas disease prevalence, such as Latin America.
Current Market Landscape
Market Size and Demand
- Chagas disease affects approximately 6-7 million individuals worldwide, predominantly in Latin America.
- The U.S. market for Benznidazole remains limited but is expanding due to increasing awareness and approval.
- Global sales are driven primarily by endemic regions where the disease burden is high.
Key Market Players
| Company |
Product Name |
Market Share |
Notes |
| Novartis |
Benznidazole |
Leading |
Approved in Latin America; limited U.S. sales |
| Mercator MedSystems |
Advocacy and distribution |
Unknown |
Developing distribution channels in the U.S. |
| Other generics |
Various |
Emerging |
Entry poised as patent restrictions lift |
Regulatory Status
- The drug previously had no FDA approval; recent approvals have enabled market entry in the U.S.
- The FDA granted an orphan drug designation to support development and market exclusivity.
- Countries like Argentina, Brazil, and Mexico have long-standing approval, with ongoing clinical trials and registration in additional markets.
Pricing Data
- In Latin America, Benznidazole prices vary: $10–$50 per treatment course, subsidized in many cases.
- In the U.S., current pricing is less established; estimated retail prices range from $500 to $1,500 per course, based on wholesale acquisition costs and limited competition.
Market Dynamics and Drivers
- Increasing global migration elevates Chagas disease awareness in non-endemic countries.
- New formulations and shorter treatment courses improve patient compliance, influencing market growth.
- Patent status and generic entry remain critical, with patent expiry anticipated within the next 3-5 years.
Price Projections (Next 5 Years)
| Year |
Estimated Retail Price Per Course |
Market Growth Rate |
Key Assumptions |
| 2023 |
$1,200 |
0% |
Initial market entry, limited competition |
| 2024 |
$1,000 |
10% |
Increased awareness, generic competition |
| 2025 |
$800 |
15% |
Patent expiration, biosimilar entry |
| 2026 |
$600 |
20% |
Price pressure from generics |
| 2027 |
$400 |
25% |
Market stabilization, increased competition |
Note: Price reductions are expected as generics enter the market and patent exclusivity ends.
Competitive Outlook
- Existing generic manufacturers are preparing to enter the U.S. and international markets.
- Price competition will likely drive prices down over the next 2–3 years.
- Strategic partnerships with government health agencies could sustain higher pricing in early stages.
Key Factors Affecting Market and Price
- Regulatory approvals: Expanded indications or simplified approval pathways could accelerate market entry.
- Patent expiration: Market prices are highly sensitive to patent and exclusivity periods.
- Manufacturing capacity: Reliable production at scale influences pricing and availability.
- Pricing policies: Government reimbursement and subsidy programs influence retail prices.
Conclusion
The U.S. market for Benznidazole (NDC 00555-0483) will likely see initial high prices, around $1,200 per course, declining over three to five years as generics enter. Global demand remains stable, driven by endemic regions, with prices in Latin America remaining lower due to subsidies and lower manufacturing costs.
Key Takeaways
- The U.S. introduces Benznidazole at an estimated $1,200 per treatment course with limited competition initially.
- Price declines are projected to reach $400–$600 within five years due to generics and patent expiry.
- The market is driven by increasing awareness, expanding approvals, and patent landscape changes.
- Competition from generics will put downward pressure on prices but could be mitigated by supply chain and manufacturing factors.
- The primary market growth opportunity exists in endemic regions with high disease prevalence.
FAQs
Q1: When is Benznidazole expected to face significant price declines?
A1: Price declines are anticipated starting around 2025–2026, correlating with patent expiry and increased generic competition.
Q2: How does patent status influence future pricing?
A2: Pending patent expiration, prices are maintained at higher levels due to exclusivity rights. Once patents expire, competition drives prices downward.
Q3: Are there biosimilar or generic alternatives available now?
A3: Not currently in the U.S., but multiple manufacturers are preparing for entry once patents expire, which will affect market prices.
Q4: What are the main barriers to market penetration?
A4: Regulatory approval delays, manufacturing capacity constraints, and limited initial acceptance due to lack of awareness.
Q5: Which regions present the largest growth opportunities?
A5: Latin American countries with high Chagas disease prevalence, especially Brazil, Argentina, and Mexico.
References
[1] World Health Organization. (2022). Chagas disease. Retrieved from https://www.who.int/news-room/fact-sheets/detail/chagas-disease
[2] FDA. (2021). FDA Approves Benznidazole for Chagas Disease. U.S. Food and Drug Administration.
[3] IQVIA. (2022). Global Pharmaceutical Market Data Report.
[4] Novartis. (2021). Annual Report.
[5] MarketWatch. (2022). Future Trends in Neglected Disease Market Analysis.
